|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Imipenem/Cilastatin (Tienam) Monotherapy in Febrile Granulocytopenic Patients |
| Ji Hoon Park, Hwan Seok Choi, Jung Back Kim, Jung Hee Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho |
| Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea |
Vol.26 Num.2 (p165~170)
|
|
|
The need for prompt antibiotic therapy in the management of febrile neutropenic patients is well established. Imipenem is the first representitive of the new thienamycin class of antibiotics. It has the broadest antibacterial activity of all antibiotics available for systemic use in humans.
We performed clinical studies to assess the efficacy and tolerability of Imipenem/Cilastatin as monotherapy in 20 febrile neutropenic patients.
Clinical response rate was 80% (16/20). Microbiologically documented infections account for 55% (11/20). Microbiologic response rate was 86% (6/7) for G(+) and 75% (3/4) for G(-) infection. No serious side effects were noted in any patients.
In conclusion, Imipenem/Cilastatin is a safe and effective antibiotics as monotherapy in febrile granulocytopenic patients.
|
|
|
Keywords : Imipenem, Febrile neutropenic patients, Infection |
|
|
|
|
|
|
|
|
